First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical…
Read moreNews & Views
Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress
Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of…
Read more
Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020
Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased…
Read more
Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of…
Read more
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of…
Read more
First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic
Telix announces first two patients dosed in phase I trial of lung & ovarian cancer…
Read more
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
Telix announces it has entered into a strategic collaboration agreement with Varian Medical…
Read more
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging…
Read more
FDA Grants Orphan Drug Designation for TLX102
Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple…
Read more
First Patient Dosed in Renal Cancer Imaging Study in Japan
Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in…
Read more